Thank you! Your submission has been received!
It looks like that email is already in our system - thanks for signing up!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
×
back to portfolio︁

Developing CRISPR-based therapies to cure viral infectious diseases.

Excision develops CRISPR-based therapies to cure viral infectious diseases. The company’s first targeted viral infection is HIV, with a pipeline to begin trials on treatments for Herpes Simplex Virus, JC Virus/PML andHepatitis B in the next ~2-3 years.

CEO
Daniel Dornbusch
Headquarters
San Francisco, Calif.
Categories
Life Sciences
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.